®! I’m your host today, Jax DiEugenio.

In today’s episode, we had the pleasure of speaking with Ignacio Blanco, MD, PhD, about the European Commission’s July 2025 conditional marketing authorization of mirdametinib (Ezmekly) for the treatment of adult and pediatric patients at least 2 years of age with symptomatic, inoperable plexiform neurofibromas (PNs) in the context of neurofibromatosis type 1 (NF1). Dr Blanco is chairman of the National Reference Center for Adult Patients with Neurofibromatosis at the Hospital Universitari Germans Trias i Pujol in Barcelona, Spain.

In our exclusive interview, Dr Blanco discussed the significance of this regulatory milestone for a population that has historically lacked effective medical options. He reviewed the pivotal phase 2b ReNeu clinial trial (NCT03962543)that supported this decision, which enrolled both adult and pediatric patients with nonresectable PNs and evaluated clinical and radiologic response rates. Dr Blanco detailed the study’s findings, including overall response rates of 41% and 52% in the adult and pediatric populations, respectively; meaningful reductions in tumor volume; improvements in patient-reported pain and quality of life; and the favorable safety profile characterized primarily by dermatologic and gastrointestinal adverse effects.

He also shared practical guidance for oncologists about identifying appropriate candidates for treatment, emphasizing the agent's role in patients with symptomatic, inoperable disease and underscoring surgery as the preferred option for operable cases. Finally, Dr Blanco reflected on the broader implications of this approval, including the potential for imatinib to be explored in other NF1-associated tumor manifestations, such as low-grade glioma and cutaneous neurofibromas, with several clinical trials currently underway.

That’s all we have for today! Thank you for listening to this episode of 

. Check back throughout the week for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit 

 is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Podcasts

Ignacio Blanco, MD, PhD, discusses the EU marketing authorization of mirdametinib for patients with symptomatic, inoperable plexiform neurofibromas.

The European Approval of Mirdametinib Expands the Treatment Paradigm for NF1-Associated Plexiform Neurofibromas: With Ignacio Blanco, MD, PhD

Ignacio Blanco, MD, PhD

“For Europeans, this is a great achievement because…we had no treatment for adult patients with NF1‑associated PNs. In the context of NF1, there are a lot of adult patients with symptomatic PNs where [there was] no possibility to offer anything.”

Ignacio Blanco, MD, PhD, director of the Catalan Reference Center for Neurofibromatosis in Barcelona, Spain, discussed the significance of the European Commission’s 

conditional marketing authorization of mirdametinib (Ezmekly)

 for the treatment of symptomatic, inoperable plexiform neurofibromas (PNs) in adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1).

PNs are complex, often debilitating tumors that arise along peripheral nerves in some patients with NF1; these PNs can cause pain, functional impairment, and disfigurement. Blanco noted that until now, no approved medical therapy existed for adult patients with symptomatic, unresectable PNs. Surgery remains the preferred approach for operable tumors, but many lesions cannot be removed safely because of their size, location, or risk of neurologic injury, he said. Moreover, these tumors do not respond to chemotherapy, and radiotherapy offers no clinical benefit.

The approval was supported by findings from the phase 2b ReNeu trial (NCT03962543), which evaluated the efficacy and safety of mirdametinib in patients with inoperable NF1‑associated PNs. This study also 

supported the February 2025 FDA approval in this indication

. ReNeu met its primary end point, with adult patients (n = 58) achieving a confirmed objective response rate (ORR) of 41% (n = 24), as determined by blinded independent central review. Pediatric patients (n = 56) experienced an ORR of 52%.

The median best percentage change in target lesion size was –41% (range, –90% to 13%) in adults and –42% (range, –91% to 48%) in pediatric patients. These radiographic responses were frequently accompanied by improvements in pain and functional outcomes, representing meaningful clinical benefit for patients with otherwise limited treatment options.

Blanco emphasized that optimal integration of mirdametinib into clinical practice will require careful patient selection. The treatment is intended for patients with symptomatic PNs that are not surgically resectable; if the tumor is operable, surgery remains the standard approach. Early identification of eligible patients through multidisciplinary evaluation will be essential to ensuring appropriate use.

As an oral MEK inhibitor, mirdametinib targets aberrant RAS/MAPK pathway signaling, a central driver of tumorigenesis in NF1. Blanco noted that, as a conditional authorization, ongoing data collection will be required to confirm long‑term benefit and safety, with post‑authorization studies expected to further define the durability of response and the treatment’s role across age groups and clinical contexts.

Videos

Ignacio Blanco, MD, PhD, discusses the significance of the European approval of mirdametinib for symptomatic, inoperable plexiform neurofibromas.

Ignacio Blanco, MD, PhD

Articles

The European Approval of Mirdametinib Expands the Treatment Paradigm for NF1-Associated Plexiform Neurofibromas: With Ignacio Blanco, MD, PhD

Dr Blanco on the Conditional EU Approval of Mirdametinib for NF1-Associated PNs